TY - JOUR
T1 - Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
AU - Hofbauer, Lorenz C.
AU - Khosla, Sundeep
AU - Dunstan, Colin R.
AU - Lacey, David L.
AU - Spelsberg, Thomas C.
AU - Riggs, B. Lawrence
PY - 1999
Y1 - 1999
N2 - The identity of the paracrine mediator(s) of the antiresorptive action of estrogen on bone cells is controversial. Osteoprotegerin (OPG) was recently identified as a soluble member of the tumor necrosis factor (TNF) receptor (TNF-R) superfamily that is secreted by osteoblast lineage cells and acts by binding to and neutralizing its cognate ligand, OPG-L, a required factor for osteoclastogenesis. OPG prevents bone loss when administered to ovariectomized rats, induces osteoporosis when ablated in knock-out mice, and induces osteopetrosis when overexpressed in transgenic mice. In conditionally immortalized, human osteoblastic hFOB/ER-3 and hFOB/ER-9 cell lines containing physiological concentrations of ~800 and ~8,000 functional estrogen receptors (ER)/nucleus, respectively, we found that 17β-estradiol dose- and time-dependently increased OPG mRNA and protein levels to maximal levels of 370% and 320%, respectively (P < 0.001); co-treatment with the 'pure' antiestrogen ICI 182,780 abrogated these effects completely. 17β-Estradiol also dose-dependently increased OPG mRNA and protein levels in normal human osteoblasts with ~400 ER/nucleus by 60% and 73%, respectively. Thus, estrogen enhancement of OPG secretion by osteoblastic cells may play a major role in the antiresorptive action of estrogen on bone.
AB - The identity of the paracrine mediator(s) of the antiresorptive action of estrogen on bone cells is controversial. Osteoprotegerin (OPG) was recently identified as a soluble member of the tumor necrosis factor (TNF) receptor (TNF-R) superfamily that is secreted by osteoblast lineage cells and acts by binding to and neutralizing its cognate ligand, OPG-L, a required factor for osteoclastogenesis. OPG prevents bone loss when administered to ovariectomized rats, induces osteoporosis when ablated in knock-out mice, and induces osteopetrosis when overexpressed in transgenic mice. In conditionally immortalized, human osteoblastic hFOB/ER-3 and hFOB/ER-9 cell lines containing physiological concentrations of ~800 and ~8,000 functional estrogen receptors (ER)/nucleus, respectively, we found that 17β-estradiol dose- and time-dependently increased OPG mRNA and protein levels to maximal levels of 370% and 320%, respectively (P < 0.001); co-treatment with the 'pure' antiestrogen ICI 182,780 abrogated these effects completely. 17β-Estradiol also dose-dependently increased OPG mRNA and protein levels in normal human osteoblasts with ~400 ER/nucleus by 60% and 73%, respectively. Thus, estrogen enhancement of OPG secretion by osteoblastic cells may play a major role in the antiresorptive action of estrogen on bone.
UR - http://www.scopus.com/inward/record.url?scp=0033304632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033304632&partnerID=8YFLogxK
U2 - 10.1210/endo.140.9.7131
DO - 10.1210/endo.140.9.7131
M3 - Article
C2 - 10465311
AN - SCOPUS:0033304632
SN - 0013-7227
VL - 140
SP - 4367
EP - 4370
JO - Endocrinology
JF - Endocrinology
IS - 9
ER -